Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Interviews from EAU 2015, Madrid, Spain
Interview with Prof. Axel Merseburger during EAU 2015, Madrid, Spain
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study
J Urol. 2015 Mar;193(3):832-8Abstract PURPOSE: Androgen deprivation represents the standard treatment for prostate cancer with osseous metastases. We explored the role of cytoreductive...
Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status
Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, Renee Lester, Christian Kollmannsberger, Nevin Murray, Ravinder Clayton, Daniel Y.C. Heng, Anthony M. Joshua, Kim N. Chi
European Urology 2015 Mar;67(3):441-7
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
Michael T. Schweizer, Xian C. Zhou, Hao Wang, Sunakshi Bassi, Michael A. Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis
European Urology, 4, 66, pages 646 - 652
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
Theodoros Karantanos, Christopher P. Evans, Bertrand Tombal, Timothy C. Thompson, Rodolfo Montironi, William B. Isaacs
European Urology, 3, 67, pages 470 - 479
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoit Baron, Mohammad Hirmand, Matthew R. Smith
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Vice Chairman of the Department of Urologic Oncology, as well as Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- May 201529Jun 20152Contact: ASCO Tel.: +1 571 483 1300 E-mail: email@example.com
- May 201529May 201530Contact: EAU Regional Offi ce Tel.: +31 26 389 0680 Fax: +31 26 389 0674 E-mail: firstname.lastname@example.org